Ocular Therapeutix shares are trading lower. The company announced topline results from the Phase 1 HELIOS study evaluating AXPAXLI in patients with moderately severe to severe non-proliferative diabetic retinopathy.
Portfolio Pulse from Benzinga Newsdesk
Ocular Therapeutix's stock trades lower following the announcement of topline results from the Phase 1 HELIOS study of AXPAXLI in patients with moderately severe to severe non-proliferative diabetic retinopathy.
April 18, 2024 | 3:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ocular Therapeutix's shares dropped after revealing topline results from their Phase 1 HELIOS study on AXPAXLI, aimed at treating moderately severe to severe non-proliferative diabetic retinopathy.
The announcement of the topline results from the Phase 1 HELIOS study likely led to investor concern about the potential efficacy and future profitability of AXPAXLI, causing a short-term negative impact on OCUL's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100